Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

sexual health in general practice

Some PCTs are boycotting the new combination statin drug simvastatin with ezetimibe (Inegy) because of cost and efficacy concerns.

The East Lancashire medicines management board ­ comprising three PCTs, a hospital trust and care trust ­ and Darlington PCT have told GPs in the areas not to prescribe the combination drug.

The move comes as the Joint British Societies are set to recommend a new optimal total cholesterol target of 4mmol/l and 2mmol/l for LDL cholesterol.

The East Lancashire group said Inegy was not recommended for prescribing in

either primary or secondary care.

A spokesman for Merck Sharp and Dohme, which manufactures Inegy with Schering-Plough, said: 'There is no cost-effectiveness data for Inegy yet.

'The submission to the MHRA was based on demonstrating that Inegy was efficacious in lowering LDL cholesterol and further outcome studies are ongoing and looking at survival.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say